Latest News and Press Releases

SINGAPORE, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...

SINGAPORE, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...

Seasoned pharmaceutical industry executive to lead Tessa’s corporate and development strategy built around its proprietary autologous and allogeneic CAR-T platforms Appointment follows Tessa’s...

Phase 1b clinical trial (ACTION) designed to evaluate TT11 as a potential second-line therapy TT11, Tessa’s autologous CD30-CAR-T therapy, is also being investigated as a monotherapy in the treatment...

SINGAPORE, June 13, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...

Proceeds to fund clinical development of Tessa’s autologous (TT11) and allogeneic (TT11X) cell therapy programs Amy Schulman and Darren Carroll from Polaris Partners have joined Tessa’s Board of...

SINGAPORE, April 04, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...

Oral poster highlights data from 14 heavily pre-treated patients enrolled in pilot stage of multicenter, open-label, single arm CHARIOT study to evaluate safety and efficacy of TT11 TT11 demonstrated...

Oral poster presentation highlights data from dose-escalation trial of allogeneic CD30.CAR EBVST cell therapy (TT11X) in patients with relapsed or refractory CD30-positive lymphomas Results...

SINGAPORE, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...